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Epilepsy is a common neurological disorder that affects over 70 million people worldwide. Despite the recent introduction of new antiseizure drugs (ASDs), about one-third
of patients with epilepsy have seizures refractory to pharmacotherapy. Early identification of patients who will become refractory to ASDs could help direct such patients
to appropriate non-pharmacological treatment, but the complexity in the temporal
patterns of epilepsy could make such identification difficult. The target hypothesis and
transporter hypothesis are the most cited theories trying to explain refractory epilepsy,
but neither theory alone fully explains the neurobiological basis of pharmacoresistance.
This review summarizes evidence for and against several major theories, including the
pharmacokinetic hypothesis, neural network hypothesis, intrinsic severity hypothesis,
gene variant hypothesis, target hypothesis, and transporter hypothesis. The discussion
is mainly focused on the transporter hypothesis, where clinical and experimental data
are discussed on multidrug transporter overexpression, substrate profiles of ASDs,
mechanism of transporter upregulation, polymorphisms of transporters, and the use
of transporter inhibitors. Finally, future perspectives are presented for the improvement
of current hypotheses and the development of treatment strategies as guided by the
current understanding of refractory epilepsy.
Keywords: epilepsy, refractory epilepsy, blood–brain barrier, P-glycoprotein, transporter hypothesis, target
hypothesis, transporter inhibition, transporter regulation

BACKGROUND: REFRACTORY EPILEPSY
Epilepsy is a common and devastating neurological disorder, affecting more than 70 million people
worldwide (1). Epilepsy patients have recurrent unprovoked seizures, which can be focal or generalized in nature (2, 3). As a first line of treatment, antiseizure drugs (ASDs) are routinely used to
control seizures. However, about one-third of epilepsy patients suffer from uncontrolled seizures
despite pharmacotherapy (4). Although a unifying and precise definition of “refractory epilepsy” is
not available (5), an epilepsy is generally considered “refractory,” “drug-resistant,” or “intractable”
when seizures cannot be controlled by at least two or three ASDs appropriate for the particular
epilepsy type (6–9). In this regard, the International League Against Epilepsy (ILAE) Task Force
proposed that “[d]rug-resistant epilepsy may be defined as failure of adequate trials of two tolerated
and appropriately chosen and used ASD schedules (whether as monotherapies or in combination)
to achieve sustained seizure freedom” (10).
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respectively (Table 1). However, since a few patients did achieve
sustained seizure freedom while on the fourth up to the seventh
medication regimen, patients who failed the first three ASD
regimens did not inevitably become refractory (19).
In patients with refractory epilepsy who do not respond to
ASDs, other therapeutic avenues are pursued including surgery
(18). In this regard, patients with refractory epilepsy caused by
distinct resectable lesions, such as hippocampal sclerosis (HS),
are potential candidates for neurosurgical removal of the lesion
(20). Epilepsy surgery has been shown to be superior to the continued use of ASDs, but the supporting clinical evidence from
randomized controlled trials is limited to temporal lobe epilepsy
(TLE) (21).
An alternative treatment approach is neurostimulation
such as vagus nerve stimulation and responsive neurostimulation (22). Vagus nerve stimulation can reduce the frequency
and/or severity of seizures (20), but some patients experience
adverse effects such as hoarseness, coughing, and dyspnea (23).
Responsive neurostimulation is a novel treatment that was
approved in the US in 2013 for adults with focal onset epilepsy
(23). Neurostimulation is an invasive, intracranial procedure,
and its efficacy does not significantly differ from other neurostimulation treatments (22).
Another option is to switch to a ketogenic diet, an approach
that is more commonly used in children with refractory epilepsy
and, while the underlying mechanism remains unknown, has

Refractory epilepsy is associated with increased morbidity
and mortality, serious psychosocial consequences, cognitive
pro
blems, and reduced quality of life (Figure 1) (11–13).
Despite the introduction of many new ASDs since 1990s, there
has been little improvement in the prognosis of common epilepsies and childhood epilepsy syndromes (14, 15). This is not
surprising given the lack of compelling evidence supporting the
superiority of new ASDs over older ones, as well as the small
placebo-corrected efficacy of adjunctive treatment with modern
ASDs (16, 17).
As part of this background section on refractory epilepsy, we
will briefly cover management, temporal patterns, and predictors
of refractory epilepsy, and then discuss the existing hypotheses
that have been proposed to explain the potential mechanisms
underlying ASD resistance.

Management of Refractory Epilepsy

Patients with refractory epilepsy carry the greatest burden of
treatment of epilepsy (18). Management strategies of refractory epilepsy fall into three main categories: pharmacotherapy,
epilepsy surgery, and alternative treatment strategies including
neurostimulation, ketogenic diet, and lifestyle changes (Figure 2)
(18). With regard to pharmacotherapy, clinical evidence shows
that patients who do not respond to two ASDs have only a small
chance to control their seizures with any additional administered
ASD (10). In a recently published prospective cohort study with
1,098 newly diagnosed epilepsy patients who were recruited
between 1982 and 2006 and were followed for up to 26 years (until
2008), Brodie et al. (19) found that 49.5% of enrolled patients
remained seizure-free (i.e., not experiencing seizures for at least
1 year) on their first ASD, while only 13.3, 3.7, 1.0, and 0.4%
of the cohort became seizure-free on the second, third, fourth,
and fifth regimen (either as monotherapy or in combination),

Figure 2 | Treatment strategies for refractory epilepsy. Current treatment
options for patients with refractory epilepsy include pharmacotherapy with
antiseizure drugs, surgical removal of the seizure focus, and alternative
approaches such as neurostimulation, ketogenic diet, and lifestyle changes.

Table 1 | Success rates of achieving seizure freedom with successive
antiseizure drug (ASD) regimens.
Number of
ASDs

1
2
3
4
5
6
7
8
9

Figure 1 | Effect of refractory epilepsy on patients’ quality of life. The circles
depict the impact of recurrent seizures on the quality of life of patients with
refractory epilepsy.
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Number of
patients

Number of
seizure-free
patients

Seizure-free patients
(% of total cohort)

1,098
398
168
68
32
16
9
3
2

543
146
41
11
4
2
2
0
0

49.5
13.3
3.7
1.0
0.4
0.2
0.2
0
0

The chance of seizure freedom declines with successive ASD regimens, most markedly
from the first to the third, among patients with epilepsy. Modified from Brodie et al. (19).
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demonstrated high efficacy rates with some studies showing that
about half the patients had a more than 50% reduction in seizure
numbers (23). However, ketogenic diet is challenging for children
due to compliance difficulties and potential short-term and longterm adverse effects and, therefore, requires regular follow-up
and clinical supervision (24).
Finally, certain lifestyle changes can help to control seizures
by minimizing seizure triggers. Common seizure triggers include
sleep deprivation, interrupted sleep, longer periods without food,
alcohol, caffeine, nicotine, drugs of abuse, psychological stress,
emotional tension, and sensory input (e.g., photosensitivity,
strobe light, and computer and video games). Therefore, sufficient
sleep, managing stress levels effectively, and following a healthy
lifestyle can help with seizure control to some extent.
In summary, pharmacotherapy is the mainstay of epilepsy
management. Epilepsy surgery and alternative measures including neurostimulation and ketogenic diet are among the therapeutic options for patients with refractory epilepsy, each with its own
advantages and disadvantages. While seizures cannot fully be
prevented by lifestyle changes alone, these changes can contribute
to improving quality of life and helping with seizure control. For
treatment purposes, each patient’s unique circumstances need
to be taken into consideration when selecting the appropriate
management strategy (18).

subsequently relapsed (27). In another study, Neligan et al. (28)
found that the intermittent pattern of seizures (i.e., having one
or more seizure-free periods which lasted for at least 2 years)
occurred in about 30% of patients with refractory epilepsy, which
was found to be associated with fewer total ASDs taken and lower
seizure frequency in the previous year when compared to the
continuous pattern of pharmacoresistance.
In summary, recent studies have shown that the temporal
patterns of refractoriness in epilepsy are more complex than
previously assumed, and up to 30% of patients with refractory
epilepsy follow a fluctuating course with periods of remission and
relapse. Based on these observations, achievement of sustained
seizure freedom may be a result of both the development course
of benign epilepsy and the treatment effect of ASDs, but it is
unclear at this point how much each of the two contributes to
long-term remission (28).

Predictors of ASD Resistance

Some have suggested that early identification of epilepsy patients
who will become refractory to ASDs could help directing these
patients to appropriate non-pharmacological treatment (3, 9, 29).
However, others have argued that such identification can be
difficult given that a considerable number of patients may have
alternating periods of relapse and remission (22). Nevertheless,
outcome studies in epilepsy have identified several factors that
have repeatedly been shown to be predictive of a poor prognosis,
including the initial response to pharmacotherapy, the underlying etiology, and a patient’s history of seizure frequency (3).
Specifically, inadequate response to initial ASD therapy has been
shown to be the most powerful indicator of refractory epilepsy
(3, 4). Symptomatic epilepsy characterized by structural brain
abnormality tends to be more ASD-resistant than idiopathic
epilepsy, which presumably has an underlying genetic basis
(13, 29). A high frequency of pretreatment seizures has also been
found to be a poor prognostic factor. On the other hand, factors
such as seizure types and electroencephalogram findings did not
consistently show significant prognostic value (3).
Together, prognostic factors are useful in predicting refractoriness in some but not all patient cases (29), and more importantly,
none of these factors explains the underlying mechanism of
pharmacoresistance (6, 11).

Temporal Patterns of Refractory Epilepsy

Pharmacoresistance in epilepsy was thought to be constitutive or
progressive, and consequently, one clinical paradigm postulated
that an early response to ASD therapy indicates a favorable prognosis (25). However, accumulating evidence now demonstrates
a higher level of complexity of the temporal patterns of epilepsy,
i.e., the clinical courses and response patterns to ASDs (15). In the
cohort study of Brodie et al. (19), 37% (408 patients) of a total of
1,098 epilepsy patients achieved sustained seizure freedom within
6 months of initiating ASD therapy, 22% of patients achieved sustained seizure freedom that was delayed for over 6 months after
treatment initiation, 16% of patients fluctuated between seizure
freedom and relapse, and 25% of patients never achieved seizure
freedom for at least 1 year. Of the 408 patients who followed the
first temporal pattern, the majority became seizure-free on the
first monotherapy regimen, 37 required a second regimen (either
an alternative monotherapy or combination regimen), and 4
required a third regimen (19). Callaghan et al. (26) conducted
a prospective cohort study with 246 ASD-resistant patients and
found that on average 5% of patients per year gained seizure
freedom for at least 1 year over 6 years of follow-up, but the risk
of relapse among those patients was relatively high with 71% after
5 years. The authors of the study also noted that the remission
was negatively correlated with the number of ASDs that failed
in a particular patient, while relapse could not be explained by
dose reductions or medication discontinuation alone. Similarly,
Neligan et al. (27) conducted a prospective cohort study in
139 patients with uncontrolled chronic epilepsy with a median
follow-up of 6.9 years and showed that 19% of patients became
seizure free and 29% of patients experienced 50–99% improvement in seizure frequency at the last follow-up. However, a
substantial proportion of the patients who experienced remission
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POTENTIAL MECHANISMS OF ASD
RESISTANCE
Understanding the mechanism(s) underlying ASD resistance
has the potential to help the development of more effective
therapeutic options for patients with refractory epilepsy. The
target hypothesis and transporter hypothesis are the most
cited theories of ASD resistance, but neither fully explains the
neurobiological basis of this phenomenon (30, 31). It is clear
that the mechanism(s) of refractory epilepsy is/are most likely
multifactorial, involving environmental, genetic, as well as disease- and drug-related factors (32, 33). In the following sections,
we discuss several hypotheses that have been proposed, starting
with the least cited to the most cited: (1) the pharmacokinetic
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hypothesis, (2) the neural network hypothesis, (3) the intrinsic
severity hypothesis, (4) the gene variant hypothesis, (5) the target
hypothesis, and finally the (6) transporter hypothesis, which will
be the main focus of this review (Figure 3).

the blood–brain barrier and reach the epileptic focus in the
brain (34).
In a case report of a pediatric patient with refractory epilepsy,
Lazarowski et al. (35) detected persistently low plasma levels of
carbamazepine, phenytoin, and valproic acid. This coincided
with increased P-glycoprotein (P-gp) protein expression levels
in endothelial cells, astrocytes, and neurons from the patient’s
resected brain tissue. In another case report of a pediatric patient
with refractory epilepsy, the same group described persistently low
phenytoin plasma levels and increased P-gp protein expression

Pharmacokinetic Hypothesis

The pharmacokinetic hypothesis proposes that overexpression
of efflux transporters in peripheral organs such as intestine, liver,
and kidney decreases ASD plasma levels in refractory epilepsy
patients, thereby reducing the amount of ASD available to cross

Figure 3 | Overview of proposed hypotheses for possible underlying mechanism(s) of antiseizure drug (ASD) resistance. (1) The Pharmacokinetic Hypothesis
proposes that overexpression of drug efflux transporters in peripheral organs decreases ASD plasma levels, thereby reducing the amount of ASD available to enter
the brain and reach the epileptic focus. (2) The Neuronal Network Hypothesis states that seizure-induced degeneration and remodeling of the neural network
suppresses the brain’s seizure control system and restricts ASDs from accessing neuronal targets. (3) The Intrinsic Severity Hypothesis proposes that common
neurobiological factors contribute to both epilepsy severity and pharmacoresistance (30). (4) The Gene Variant Hypothesis states that variations in genes associated
with ASD pharmacokinetics and pharmacodynamics cause inherent pharmacoresistance. These genes include metabolic enzymes, ion channels, and certain
neurotransmitter receptors that are targets for ASDs. (5) The Target Hypothesis postulates that alterations in the properties of ASD targets, such as changes in
voltage-gated ion channels and neurotransmitter receptors (e.g., GABAA receptor), result in decreased drug sensitivity and thus lead to refractoriness. (6) The
Transporter Hypothesis states that overexpression of ASD efflux transporters at the blood–brain barrier in epilepsy leads to decreased ASD brain uptake and thus
ASD resistance.
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analyzed by immunohistochemistry in resected epileptic brain
tissue (36). The authors also reported that the P-gp substrate,
99m
Tc-hexakis-2-methoxyisobutylisonitrile, demonstrated increased
hepatic clearance in eight patients with refractory epilepsy compared to seven normal subjects and four patients with controlled
epilepsy (37). Based on this finding, the authors postulated that
the liver is involved in potential pharmacokinetic changes that
could contribute to ASD resistance (34).
In the two cases described above, the authors argued that
subtherapeutic ASD blood levels could not be explained by overexpression of P-gp at the blood–brain barrier and in neurons.
Instead, the authors suggested overexpression of P-gp or other
efflux transporters in the periphery as an additional mechanism
for refractory epilepsy, especially in patients who presented with
persistently low ASD plasma levels (34). While this explanation
is plausible, the authors postulated their hypothesis based on only
two case studies, and it is unclear at this point if their observation is limited to these cases or a wider-spread phenomenon. In
addition, the authors did not provide any additional evidence
from human samples and/or from rodent epilepsy models to
substantiate their statements.
Support for the pharmacokinetic hypothesis also comes from
studies showing persistent low ASDs levels in patients with refractory epilepsy regardless of P-gp overexpression. For example, in a
clinical study of 70 patients treated with oral phenytoin, Iwamoto
et al. (38) found that the mean free phenytoin plasma concentration was significantly higher in patients with a complete response
to phenytoin compared to patients with a partial response. This
effect was independent of the phenytoin dose, and the results
suggest that the free phenytoin concentration could be useful
for monitoring ASDs effects in patients receiving phenytoin
monotherapy. In a retrospective study, Paul and coworkers (39)
found in 80% of patients with refractory epilepsy that lamotrigine
serum levels were decreased by 20% after surgery compared to
preoperative levels. In six patients, seizures were observed within
the first 2 weeks after surgery. In three of these patients, seizures
occurred after reaching the nadir of lamotrigine plasma levels.
Therefore, the authors propose counteracting a postoperative
reduction in serum lamotrigine levels by augmenting the preoperative drug dose and close monitoring of drug serum levels
after surgery (39). Dalaklioglu (40) reported a high frequency
of subtherapeutic ASD plasma levels in patients with refractory
epilepsy. Further, Fagiolino et al. (41) conducted a clinical study
and observed that the saliva drug concentration ratio from two
sequentially collected samples could be utilized to detect systemic
clearance changes. This could be useful to predict plasma levels
of ASDs such as carbamazepine and phenytoin that are known to
induce drug efflux transporters during chronic treatment.
Other studies suggest an association between peripheral
expression levels of metabolizing enzymes and efflux transporters
on the one hand and plasma ASD concentrations on the other
hand. Kerb et al. (42) reported a clinical study conducted in 96
healthy Turkish volunteers. In this study, the combined analysis of
CYP2C9 and multidrug resistance protein 1 (MDR1) genotypes
had better predictive value for phenytoin plasma concentrations than CYP2C9 analysis alone. Simon et al. (43) found that
increased intestinal P-gp expression levels had a weak association
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with low carbamazepine plasma concentrations, and increased
intestinal MRP2 expression levels were weakly related to high
carbamazepine doses in 29 epilepsy patients. Nevertheless,
unlike the case reports by Lazarowski et al., neither study directly
addressed ASD response.
In addition, data from clinical studies show that ASDresponsive and ASD-resistant patients display adverse events to
the same extent (44, 45), suggesting similar plasma ASD levels in
the two groups of patients. One explanation for this observation is
that efflux transporter overexpression is restricted to the epileptic
focus. This observation also suggests that same plasma ASD concentrations are due to same enzyme and transporter expression
levels in peripheral organs. While both of these explanations are
plausible, one does not necessarily lead to the other.
Furthermore, some animal studies do not support the pharmacokinetic hypothesis. In these studies, differences in ASD
plasma concentrations and/or side effects have not been observed
between ASD responders and non-responders (46, 47), and
administration of transporter inhibitors enhanced anticonvulsant activity of the ASD without changing its pharmacokinetics
(44, 47, 48).
Together, the pharmacokinetic hypothesis of refractory epi
lepsy as a stand-alone theory is difficult to validate. One can
argue that because abnormalities in ASD plasma concentrations
can be readily captured by therapeutic drug monitoring, pharmacokinetic variability is probably not a major contributor to
pharmacoresistance in situations where ASD doses are adjusted
accordingly. This argument, however, is further complicated
because therapeutic ASD plasma concentrations vary among
patients, and no one specific therapeutic ASD concentration
range is applicable to all patients (49, 50). The optimal plasma
concentration for a patient is partially related to the patient’s
seizure type and disease severity, as well as the pharmacodynamic
characteristics of the specific ASD(s) used (49, 50). For newer
ASDs, wide ranges of therapeutic serum concentrations have
also been reported, and concentrations corresponding to toxicity
and non-response can overlap considerably (50). Therefore, it
seems more appropriate to adjust ASD dosages on an individual
basis than to strictly conform to reference therapeutic plasma
concentrations (49).

Neural Network Hypothesis

Recently, Fang et al. (51) proposed the neural network hypothesis,
which states that seizure-induced degeneration and remodeling
of the neural network suppress the endogenous antiseizure
system and inhibit ASDs from accessing neuronal targets.
Specifically, molecular evidence shows that the growth cone at
the tip of an exon receives abnormally expressed guidance and
signaling molecules in the epileptic brain (51). In addition, the
formation of new excitatory circuits as a result of progressive
sprouting has been widely investigated in TLE (51). The authors
postulate that neurogenesis and astrogliosis in TLE could contribute to the development of abnormal neural networks and
eventually ASD resistance. However, the major weakness of this
hypothesis is that alterations in the neural network do not lead
to refractoriness in all epilepsy patients, and therefore, further
biological evidence on potential differences in the changes of
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brain plasticity between drug-responsive and drug-resistant
epilepsy is needed to support this hypothesis (51).

different study, Tate et al. (60) also revealed a significant correlation between CYP2C9*3 and a reduced dose requirement of phenytoin, and Ufer et al. (62) found in a specific subgroup of patients
significantly more heterozygous CYP2C8*4 and CYP2C9*3
variant allele carriers among ASD responders compared to ASD
non-responders.
Voltage-gated sodium channels are the target of several com
monly used ASDs, including carbamazepine, phenytoin, lamotrigine, and valproate (63). Voltage-gated sodium channels consist
of one α subunit and two β subunits. The isoforms of the α subunits,
Nav1.1, 1.2, 1.3, and 1.8, are encoded by the SCN1A, 2A, 3A, and
8A genes, respectively (64). Using a haplotype-tagging strategy,
Tate et al. (60) demonstrated a significant correlation between an
intronic single nucleotide polymorphism (SNP) in the SCN1A
gene (IVS5-91G>A or rs3812718) and the maximum required
doses of carbamazepine and phenytoin in groups of 425 and 281
English patients, respectively. In a follow-up study in 168 Chinese
epilepsy patients on phenytoin treatment, Tate et al. (65) found
that the same polymorphism was correlated with phenytoin
serum levels at maintenance dose, but not with the maintenance
or maximum dose of phenytoin. In a study including 228 Japanese
patients with epilepsy, Abe et al. (66) demonstrated a significant
association between the frequency of the SCN1A IVS5-91 AA
genotype and resistance to carbamazepine, but not the carbamazepine maximum or maintenance dose. Kwan et al. (64) genotyped
tagging and candidate SNPs of SCN1A, 2A, and 3A in 471 Chinese
patients with epilepsy and reported a significant correlation
between an intronic SNP in SCN2A (IVS7-32A>G, rs2304016)
and responsiveness to various ASDs, but the polymorphism did
not significantly alter SCN2A mRNA levels in resected brain tissue
or peripheral white blood cells. On the other hand, the association between IVS5-91G>A in the SCN1A gene and ASD response
was not observed in this study (64). Several more recent studies
explored the relationship between other SNPs in the sodium
channel genes and drug response in epilepsy, including SCN1A
c.3184 A>G (rs2298771) and SCN2A c.56 G>A (rs17183814),
both of which were found to be functionally significant in
some neurological disorders (67–69). In a study including 336
epilepsy patients from the northern part of India, Lakhan et al.
(67) reported a significant association between the variant allele
frequency of SCN2A c.56 G>A SNP and ASD resistance. This
finding was confirmed by Kumari et al. (68) in another study with
402 epilepsy patients from the same geographic region. Although
Lakhan et al. and Kumari et al. did not reveal an association
between SCN1A c.3184 A>G SNP and ASD resistance, Abo El
Fotoh et al. (69) demonstrated a significant relationship between
the AG genotype or G allele and ASD resistance in Egyptian
children with epilepsy.
In summary, with the gene variant hypothesis, currently the
strongest evidence exists for the association between CYP2C9
polymorphism and phenytoin dose requirement. Although the
relationship between various SCN1A and SCN2A polymorphisms
and ASD dose requirement and/or response has been explored
in a number of genetic association studies, the study results have
been inconsistent, and genetic associations identified so far need
further confirmation in larger populations. In addition, given
the low frequency of certain alleles and the multifactorial nature

Intrinsic Severity Hypothesis

The intrinsic severity hypothesis states that common neurobiological factors contribute to both epilepsy severity and pharmacoresistance (30). In other words, pharmacoresistance is inherent
to the disease severity, which could exist on a continuum ranging
from mild to severe (52).
In this regard, data from reports supporting the intrinsic
severity hypothesis suggest that high pretreatment seizure frequency is an important predictor for refractory epilepsy (53–55).
Based on these reports, it is tempting to draw an association
between ASD resistance and the experimental electrical kindling,
in which repeated electrical stimulation at a subconvulsive level
can eventually induce spontaneous recurrent seizures in animals
(4, 13). However, a randomized clinical study demonstrated
that starting ASD treatment after the first tonic–clonic seizure
did not improve the prognosis of epilepsy (56). In fact, the same
probability of becoming seizure-free for 1 or 2 years was seen in
patients who were treated after the first seizure and those who
received treatment after seizure recurrence (56). A similar conclusion was drawn from a cohort study in children with epilepsy,
which showed that ASD administration at some point during the
first 10 seizures had no aggravating effect on achieving seizure
control or early remission (57). In a randomized study in 1,847
epilepsy patients, the authors compared immediate and deferred
treatment with ASDs and found that immediate treatment
was associated with seizure reduction in the first 1–2 years, but
rates of long-term remission did not differ between the two
groups (58).
Therefore, such findings argue against the notion of a kindlinglike process where the likelihood of ASD resistance is increased
with the number of pretreatment seizures. Instead, high seizure
frequency prior to ASD treatment could be the result of pathophysiological changes characterizing refractory epilepsy (4). An
alternative interpretation of the epidemiological data resulted
in the intrinsic severity hypothesis. While this theory appears
biologically plausible, it does not adequately apply to epilepsy
types that demonstrate a fluctuating or evolving pattern of ASD
resistance (30). In addition, there is little evidence supporting a
direct mechanistic link between the severity of epilepsy and ASD
response (59). Therefore, it has been suggested that the intrinsic
severity theory alone does not sufficiently explain pharmacoresistance in epilepsy (59).

Gene Variant Hypothesis

The gene variant hypothesis states that variations in genes associated with ASD pharmacokinetics and pharmacodynamics cause
inherent pharmacoresistance (17). Specifically, variations in
genes that encode enzymes that metabolize ASDs or ion channels
and neurotransmitter receptors targeted by ASDs can potentially
affect ASD response (33).
Phenytoin is metabolized by CYP2C9 (90%) and CYP2C19
(60). Van der Weide et al. (61) reported strong associations
between the low activity alleles of CYP2C9 (CYP2C9*2 and
CYP2C9*3) and a reduced phenytoin dose requirement. In a
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of refractory epilepsy, it is possible that individual markers may
not have a large enough clinical impact on overall ASD response
(64). Together, the impact of the gene variant hypothesis as a
stand-alone theory is mainly limited by inconsistencies and poor
reproducibility of study findings. Nevertheless, improvement in
genomic technologies and research methodology is expected to
increase the chances of uncovering truly predictive genetic markers for ASD resistance and further the advancement of epilepsy
pharmacogenomics (70).

barrier in epilepsy decreases ASD brain uptake, thus causing
ASD resistance similar to pharmacoresistance in cancer (2).
Since this initial proposal by Tishler et al., other ABC transporters have been shown to be upregulated at the blood–brain barrier
in epilepsy and the transporter hypothesis has been intensively
investigated (45). The transporter hypothesis is based on two
assumptions: (1) overexpression of efflux transporters correlates
with pharmacoresistance in epilepsy and (2) ASDs are subject to
active transport by efflux transporters (78). In the following, we
will describe the roles P-gp, the MRPs, and BCRP have in epilepsy
in more detail.

Target Hypothesis

The target hypothesis of refractory epilepsy postulates that
alterations in the properties of ASD targets, such as compositional changes in voltage-gated ion channels and neurotransmitter receptors, result in decreased drug sensitivity and thus lead
to refractoriness (63, 71). For example, loss of use-dependent
blockade of voltage-gated sodium channels in dentate granule
cells by carbamazepine was observed in rats after pilocarpineinduced epilepsy and in resected hippocampal tissue from
patients with carbamazepine-resistant TLE (71). However, this
loss in efficacy due to a potential change in the molecular target
has so far only been reported for carbamazepine and has not been
demonstrated to occur with other ASDs that block sodium channels (72). Reduced sensitivity of GABAA receptors to agents that
bind to the benzodiazepine receptor site 1 has been reported in
the pilocarpine model of epilepsy (63), and data from two other
studies showed changes in GABAA receptor subtypes in brain tissue from patients with refractory TLE (73, 74). Overall, evidence
supporting the target hypothesis mainly describes the loss of
use-dependent channel blockade by carbamazepine and comes
from resected human brain tissue (72, 75). The fact that most
refractory patients are resistant to several ASDs acting on different therapeutic targets undermines the general utility of the target
hypothesis and instead supports the existence of a mechanism
non-specific to individual ASDs (2).

P-Glycoprotein

P-glycoprotein is also known as MDR1 (old nomenclature)
or ATP-binding cassette subfamily B member 1 (ABCB1, new
nomenclature). P-gp is encoded by the MDR1 (ABCB1) gene in
humans and by the mdr1a/mdr1b genes in rodents (79). P-gp protein is expressed in various barrier and excretory tissues such as
intestine, liver, and kidney, where it actively exports hydrophobic
and amphipathic molecules from the inside of cells or membranes
to the outside (80, 81). This physiological function of exporting naturally occurring toxins and xenobiotics is considered
to be a critical defense mechanism (82). In the normal human
brain, P-gp is expressed in the luminal plasma membrane of the
brain capillary endothelial cells that constitute the blood–brain
barrier as well as in the apical membrane (facing the cerebrospinal fluid) of the choroid plexus epithelial cells that form the
blood–cerebrospinal fluid barrier (83). P-gp expression is only
marginally detectable in neurons or glial cells under normal,
physiological conditions (32). In rodents, the mdr1a isoform is
mainly expressed in endothelial cells of the blood–brain barrier,
and mdr1b is primarily found in astrocytes (84).

Multidrug Resistance-Associated Proteins

The MRP family (ATP-binding cassette subfamily C, ABCC)
comprises nine members (MRPs 1–9 or ABCCs 1–6 and 10–12)
(85). MRPs are expressed in the membranes of various cell types,
such as hepatocytes, kidney proximal tubular epithelial cells,
enterocytes, and brain endothelial cells, where they transport a
wide variety of mostly anionic endogenous and exogenous compounds and their metabolites (85). The luminal and/or basolateral
localization of MRP proteins is often specific to a certain cell type
(86). MRP1 is expressed at the basolateral membrane of choroid
plexus epithelial cells and at low levels at the luminal membrane
of endothelial cells at the blood–brain barrier (86). MRP2 is
exclusively expressed at the luminal membrane of polarized cells,
including brain endothelial cells (85). MRP4 and MRP5 have
also been found to be apically localized in human brain capillary
endothelial cells (87), whereas neuronal or glial MRP1 and MRP2
expression in the normal brain has not been consistently reported
in the literature (32, 83, 88).

Transporter Hypothesis

Multidrug resistance due to efflux transporters has been studied
extensively in tumor cells. The best understood efflux transporters are members of the ABC (ATP-binding cassette) superfamily
subfamilies B, C, and G, specifically P-gp (ABCB1 or MDR1),
the multidrug resistance-associated proteins (MRP1, ABCC1;
MRP2, ABCC2), and breast cancer resistance protein (BCRP,
ABCG2) (75). Members of the ABC superfamily are ATP-driven
membrane pumps that actively transport substrates, including
a large number of therapeutic drugs, against their concentration gradient out of cells and tissues, limiting their entry into
the respective organs and thereby causing resistance (75). For
example, P-gp, BCRP, and some multidrug resistance-associated
proteins (MRPs) hinder chemotherapeutic drugs from entering
cancer cells. Thus, ABC transporter overexpression in cancer
causes resistance to chemotherapeutic drugs resulting in poor
prognosis in cancer patients (32, 76).
In 1995, Tishler et al. (77) found that MDR1 mRNA was
overexpressed in brain tissue resected from patients with
refractory epilepsy and postulated the transporter hypothesis
of refractory epilepsy: P-gp overexpression at the blood–brain
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Breast Cancer Resistance Protein

Breast Cancer Resistance Protein (ATP-binding cassette subfamily G member 2 or ABCG2) is prominently expressed at the apical
membrane in various cell types, including hepatocytes, intestinal
epithelial cells, kidney proximal tubular cells, and the endothelial
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cells of the blood–brain barrier (76, 89). Similar to P-gp, BCRP
transports a wide variety of substrates, and its tissue distribution
contributes to its important roles in restricting absorption and
facilitating elimination of drugs and xenobiotics (76).

of TLE with sustained spontaneous recurrent seizures developed
after electrically induced status epilepticus (SE) (46). Using this
model, the authors demonstrated that epileptic rats that did not
respond to phenobarbital had higher P-gp expression levels in
the capillary endothelial cells of the limbic brain region compared to rats that responded to phenobarbital (46). In humans,
non-invasive positron emission tomography (PET) imaging is
one approach to directly compare P-gp functional activity in
ASD-responsive vs. ASD-resistant patients by determining tissue concentrations of PET tracers that are P-gp substrates (97).
In a small pilot PET study using the P-gp substrate (R)-[11C]
verapamil, Langer et al. (98) reported no significant differences
in pharmacokinetic parameters between epileptogenic and nonepileptogenic brain regions in patients with refractory unilateral
TLE. Subsequently, Feldmann et al. (99) conducted a PET study
in 14 patients with ASD-refractory TLE, 8 patients with ASDcontrolled TLE, and 13 healthy control individuals. In patients
with refractory TLE, (R)-[11C]verapamil brain uptake was
reduced compared to seizure-free patients, and the increase in
(R)-[11C]verapamil brain uptake following the administration
of tariquidar (P-gp inhibitor) was smaller compared to healthy
individuals; both observations are consistent with higher P-gp
activity at the blood–brain barrier in patients with refractory TLE
(99). This study was the first to provide direct in vivo evidence of
P-gp overactivity in patients with refractory epilepsy. In a more
recent study of Shin et al. (100) in six patients with ASD-resistant
epilepsy, five patients with ASD-responsive epilepsy, and eight
healthy subjects, (R)-[11C]verapamil PET and magnetic resonance
(MR) imaging with cyclosporine A (P-gp inhibitor) demonstrated
significant asymmetry of P-gp expression in refractory patients
compared to both seizure-free patients and healthy subjects,
suggesting higher P-gp expression and lower uptake of (R)-[11C]
verapamil in the group of patients with refractory epilepsy. Larger
PET studies comparing transporter activity at the blood–brain
barrier in ASD-responsive and ASD-resistant patients are needed
in the future to confirm the results presented above.
In summary, overexpression of ABC multidrug efflux transporters at the blood–brain barrier observed in numerous studies
forms the foundation of the transporter hypothesis of refractory
epilepsy. In addition, astrocytic expression of these transporters
has been described, which could also present another barrier and
contribute to reduced ASD uptake in epileptic tissue (75, 88).

Overexpression of Efflux Transporters in Refractory Epilepsy

P-glycoprotein overexpression in epileptogenic brain tissue
in patients with refractory epilepsy has been documented in
numerous studies (45). Tishler et al. (77) were the first to demonstrate overexpression of MDR1 mRNA in 11 out of 19 resected
brain specimens from patients with refractory focal epilepsy.
Subsequently, increased levels of P-gp protein expression have
also been observed in the brain capillary endothelium of resected
brain tissue from patients with refractory epilepsy, where P-gp
overexpression was localized to the luminal membrane of the brain
capillary endothelium by immunohistochemistry (80, 90). P-gp
overexpression was also detected in astrocytes and/or dysplastic
neurons in common pathological causes of refractory epilepsy,
including dysembryoplastic neuroepithelial tumors (DNT), HS,
and focal cortical dysplasia (FCD) (32, 84, 88, 91–93).
MRP1 overexpression in astrocytes and/or dysplastic neurons
in HS, DNT, and FCD has also been described in a number of
studies (32, 88, 91, 93). The results from these studies confirm that
MRP1 protein expression levels in astrocytes and neurons from
brain tissue of epilepsy patients are significantly increased compared to brain tissue from healthy individuals, while endothelial
MRP1 expression did not differ between the two (94).
Dombrowski et al. (80) were the first to report increased MRP2
and MRP5 mRNA levels in endothelial cells isolated from epileptic
brain tissue of patients with refractory epilepsy compared to control endothelial cells from human umbilical vein and aneurysm
domes. Aronica et al. (88) reported MRP2 protein overexpression
in endothelial cells and astrocytes in HS tissue specimens of
adult patients with TLE. The same observation was reported by
Vogelgesang et al. (92) for MRP2 protein in DNT tissue from
patients with refractory epilepsy. In the same study, the authors
also observed MRP5 protein overexpression in dysplastic neurons,
astrocytes, and brain endothelial cells in epileptogenic tissue.
Data from few studies comparing BCRP expression in control
and epileptic human brain tissue demonstrated the constitutive
expression of BCRP in the brain capillary endothelium, but these
data do not show differences in BCRP expression levels between
the groups (89, 90, 92, 95). Due to the current lack of evidence
on BCRP overexpression in human epileptic brain tissue, BCRP
is unlikely a major player in ASD resistance as proposed by the
transporter hypothesis.
Although increased mRNA and protein expression levels of
P-gp and MRPs have been demonstrated in resected brain tissue
from patients with ASD-resistant epilepsy, previous studies did
not include proper controls, as it is generally difficult to obtain
brain tissue from either patients with drug-responsive epilepsy or
from healthy subjects without brain disease. Therefore, it is still
unclear if overexpression of efflux transporters correlates with and
potentially causes ASD resistance, or if it is an epiphenomenon
of epilepsy in humans that is unrelated to ASD resistance (96).
In this regard, Volk and Löscher established a correlation
between ASD response and P-gp expression levels in a rat model
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Transport of ASDs by Efflux Transporters

Conclusive evidence that ASDs are transported by efflux transporters at therapeutic concentrations is considered the weak link
in the transporter hypothesis (101). Early studies suggested that
several ASDs may be substrates for P-gp and/or MRPs. However,
researchers from different studies used different models, methodologies, and analytical methods with different sensitivities
which yielded inconsistent results. Researchers who attempted
to identify ASDs as substrates of P-gp, MRPs, and/or BCRP
mainly used three approaches: transporter-overexpressing cell
lines, transporter inhibition in cell lines and/or in animals, and
transporter gene knockout mice (82). Each of these approaches
has its own strengths and weaknesses. For example, transporteroverexpressing cell lines only allow in vitro analysis. Transporter
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inhibitors may lack specificity and interact with more than one
transporter, and knockout mice may show potential compensatory upregulation of other transporters, which may complicate
the situation (78). Therefore, all three approaches may need to
be used together in one thorough study to obtain conclusive data
(78). In addition, compared to chemotherapeutic drugs that are
usually high-affinity substrates for P-gp and MRPs, ASDs are
weak substrates for the efflux transporters and more easily cross
the blood–brain barrier under physiological conditions (12).

phenytoin and levetiracetam were transported by mouse P-gp
only, while carbamazepine was not transported by human or
mouse P-gp (109). Luna-Tortós et al. (110) pointed out that
conventional bidirectional transport assays may not be suitable
to identify ASDs as P-gp substrates due to the highly permeable nature of most ASDs. Using a modified transport assay
(concentration equilibrium transport assay; CETA) which allows
evaluating active transport separately from passive permeability,
Luna-Tortós et al. detected P-gp transport of phenytoin, phenobarbital, lamotrigine, levetiracetam, and topiramate, but not
carbamazepine in MDR1-transfected LLC-PK1 cells (110, 111).
Zhang et al. (101) used both the cell monolayer bidirectional
assay and CETA in MDR1-transfected MDCKII and LLC-PK1
cells to test if phenytoin, phenobarbital, or ethosuximide were
transported by P-gp. Results from the CETA experiments suggested concentration-dependent P-gp transport of phenytoin in
both MDCKII-MDR1 and LLC-PK1-MDR1 cells and transport
of phenobarbital only in MDCKII-MDR1 cells. In conventional
bidirectional transport experiments, however, P-gp-mediated
phenytoin transport was minimal, indicating that either cell
monolayer permeability may have been too high to detect any
differences and/or that CETA has superior sensitivity in studying
the active transport of highly permeable compounds (101).
Nonetheless, the results from in vitro experiments using cell
lines transfected with human proteins should be confirmed
using in vivo approaches such as PET (112). Verbeek et al. (113)
conducted a PET study in rats and concluded that [11C]phenytoin
was a weak P-gp substrate, as demonstrated by the increase in the
brain-to-plasma concentration ratio after P-gp inhibition with
tariquidar. In contrast, [11C]methylphenobarbital was not shown
to be transported by P-gp in a similarly designed PET study in
rats and mice (114). At present, data from studies using resected
human brain or from clinical trials aimed at identifying if P-gp
transports ASDs are limited (96). The only clinical evidence
linking overexpression of blood–brain barrier P-gp to reduced
ASD brain levels came from a pilot study by Marchi et al. (115).
These authors demonstrated an inverse correlation between the
brain–plasma concentration ratio of the major active metabolite
of oxcarbazepine, 10,11-dihydro-10-hydroxy-5H-dibenzo(b,f)
azepine-5-carboxamide (10,11-dihydro-10-hydroxycarbamazepine), and the MDR1 mRNA brain expression levels in resected
epileptic tissue from patients with refractory epilepsy (115).
Since different models yield different results, both in vivo
and in vitro data seem to be needed to identify which ASDs are
substrates for which transporter. In this regard, by combining
the available evidence (as of 2012), Zhang et al. (96) suggested
that lamotrigine, oxcarbazepine, phenobarbital, and phenytoin
are considered definite P-gp substrates, because P-gp-mediated
transport of these ASDs has been supported by both in vivo and
in vitro evidence.

ASD Transport by P-gp. P-glycoprotein transports a wide range
of structurally and functionally diverse compounds, which are
primarily hydrophobic and amphipathic compounds (81). Most
ASDs are planar lipophilic molecules, and therefore, theoretically
many ASDs should be P-gp substrates (11, 80).
The first report of P-gp-mediated transport of an ASD came
from Tishler et al. (77), who reported lower steady-state intracellular phenytoin concentrations in MDR1-expressing neuroectodermal cells as compared to MDR1-negative cells. P-gp-mediated
phenytoin transport was also demonstrated in vivo using brain
microdialysis in normal rats after administration of P-gp inhibitors (79), in rats with SE-induced P-gp upregulation (44), and
in mdr1a/b knockout mice (102). Phenobarbital, lamotrigine,
felbamate, and oxcarbazepine were shown to be transported by
P-gp in rat brain microdialysis studies using verapamil as a P-gp
inhibitor (103, 104). In contrast, one study using mdr1a knockout
mice and wild-type control mice showed that out of the seven
commonly used ASDs (phenobarbital, phenytoin, carbamazepine, vigabatrin, lamotrigine, gabapentin, and topiramate), only
topiramate appeared to be a P-gp substrate (82). However, remaining mdr1b expression and potential compensatory upregulation
of other efflux transporters in mdr1a knockout mice could be
limitations of the study (82).
Previous studies on P-gp-mediated transport of carbamazepine
yielded inconsistent results (63). Owen et al. (105) concluded that
carbamazepine was not a substrate for P-gp based on results from
experiments with mdr1a/b knockout mice, P-gp-overexpressing
Caco-2 cells, and flow cytometry in human lymphocytes using
rhodamine 123. In contrast, two other studies, one using mdr1a/b
knockout mice and the other using in vivo microdialysis with
verapamil, supported that P-gp transports carbamazepine
(102, 106). Data from another microdialysis study in rat suggest
that P-gp does not transport levetiracetam (107). Baltes et al.
(108) demonstrated that P-gp does also not transport valproic
acid by using efflux assays with transfected MDCKII (dog kidney)
cells and LLC-PK1 (pig kidney) cells and rat brain microdialysis
with the P-gp inhibitors verapamil and tariquidar.
While most of the earlier studies focused on rodent transporters, later and more recent studies used cell lines transfected with
human MDR1 or MRPs in order to identify potential species
differences in substrate spectrum or transport efficiency of the
transporters. Baltes et al. (109) conducted bidirectional transport
assays in monolayers of MDCKII and LLC-PK1 cells transfected
with complementary DNA containing either MDR1, MRP2,
mdr1a, or mdr1b sequences to study the transport of phenytoin,
levetiracetam, and carbamazepine by human and mouse P-gp.
The authors concluded that in transfected LLC-PK1 cells, both
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ASD Transport by MRPs. Multidrug resistance-associated proteins transport neutral organic drugs and amphiphilic organic
anions including drugs conjugated to glutathione, sulfate, glucuronate, and phosphate (85, 86). Thus, it is possible that MRPs
transport a number of ASDs and/or their metabolites and limit
their access to the brain (32).
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Phenytoin transport by MRP1 and/or MRP2 was shown
in vivo in normal rats using brain microdialysis with the MRP1/2
inhibitor probenecid (116), in TR− mutant rats that lack MRP2
(117), and in rats with seizure-induced MRP1 upregulation (118).
Carbamazepine and oxcarbazepine were shown to be substrates
of MRP1 and/or MRP2 in microdialysis in vivo studies with
probenecid (104, 106). Valproic acid was the first ASD found to
be a substrate for MRPs in brain endothelial cells (119), but Baltes
et al. (108) could not confirm this finding using efflux assays with
transfected LLC-PK1 and MDCKII cells and rat brain microdialysis with the MRP inhibitors probenecid and MK571. Similarly,
using brain microdialysis in rats, Potschka et al. (107) showed
that levetiracetam was not transported by MRP1/2.
Baltes et al. (109) conducted bidirectional transport assays
in monolayers of MRP2-transfected MDCKII kidney cells, and
none of the ASDs tested (phenytoin, levetiracetam, carbamazepine) was found to be transported by MRP2. Using CETA in
MDCKII kidney cells transfected with human MRP1, MRP2, or
MRP5, Luna-Tortós et al. reported that none of the ASDs tested
(topiramate, valproate, carbamazepine, phenytoin, levetiracetam,
lamotrigine, and phenobarbital) was transported by any of those
MRPs (111, 112). In vivo studies may be needed to confirm the
findings from in vitro experiments, but few clinical studies have
focused on studying the relationship between ASDs and MRPs.

a combination of both are likely to be the major contributors to
efflux transporter overexpression at the blood–brain barrier in
epilepsy (59).
Experimental data mostly from animal studies support that
P-gp upregulation in epileptic regions of the brain occurs mainly
as a result of seizure activity (124). Rizzi et al. (102) reported
mdr1 mRNA upregulation in brain of mice acutely after kainic
acid-induced seizures and in rats with self-sustained seizures
after electrically induced SE. Using a rat TLE model in which
seizures developed spontaneously after electrically induced SE,
van Vliet et al. (84) demonstrated that mdr1a mRNA, mdr1b
mRNA, and P-gp protein levels increased within 1 week after SE.
Specifically, chronic epileptic rats had persistent overexpression
of mdr1b mRNA and P-gp protein in endothelial and glial-like
cells of the ventral temporal lobe, with higher P-gp levels in rats
that had more seizure activity (84). Levels of mdr1a mRNA and
P-gp protein levels also increased in whole tissue samples of the
temporal hippocampus and the parahippocampal cortex that
are involved in epileptogenesis (44). In another study, Bankstahl
and Löscher showed overexpression of P-gp protein in brain
capillary endothelial cells 48 h after SE in two rat models, the
lithium/pilocarpine model and the basolateral amygdala electrical stimulation model (125). van Vliet et al. (126) also reported
increased MRP1, MRP2, and BCRP protein expression levels in
rat astrocytes and cerebral blood vessels after acute SE and in
chronic epilepsy. Similar to the finding with P-gp, overexpression
of these transporters was greater in chronic epileptic rats that
demonstrated progression of epilepsy (126). Recent research in
the field has postulated two main mechanisms leading to efflux
transporter overexpression in the brain in epilepsy: (1) ASDmediated induction of efflux transporters via nuclear receptors
and (2) seizure-induced signaling causing efflux transporter
overexpression.
With regard to the first mechanism, studies on whether ASDs
induce efflux transporter overexpression have yielded inconsistent
results. Rizzi et al. (102) reported that twice daily intraperitoneal
administration of 30 mg/kg phenytoin or 15 mg/kg carbamazepine for 7 days did not alter mdr1 mRNA expression levels in the
mouse hippocampus. However, P-gp expression levels are highest
in brain capillaries, and thus, such increases would be masked by
using total brain samples due to dilution (brain capillaries make
up only 1% of brain volume) (127). Seegers et al. (128) found
that giving rats 30 mg/kg phenobarbital or 50 mg/kg phenytoin
(following 75 mg/kg on the first day) intraperitoneally daily for
11 days did not significantly increase endothelial or parenchymal
P-gp protein expression levels in various brain regions (frontal
and parietal cortex, basolateral amygdala, hippocampus, dentate
gyrus, piriform cortex, substantia nigra pars reticulata, and
cerebellum).
In contrast, in the Coriaria lactone-induced rat SE model,
Wang-Tilz et al. (129) reported that giving orally 125 mg/kg
carbamazepine or 187.5 mg/kg valproic acid daily increased P-gp
expression in astrocytes and endothelial cells, particularly in the
hippocampus, the temporal, frontal, and parietal lobes of the
brain, whereas giving daily 100 mg/kg topiramate or 125 mg/kg
lamotrigine orally for 30 days did not affect P-gp expression levels.
However, studies have shown that seizures induce brain capillary

ASD Transport by BCRP. Substrate specificity of BCRP significantly overlaps with that of P-gp (120). However, the role
of BCRP in ASD resistance is less well studied in comparison
to P-gp or the MRPs (121). Using BCRP-transfected MDCKII
cells, Cerveny et al. (122) reported that none of the tested ASDs
(phenobarbital, phenytoin, ethosuximide, primidone, valproate,
carbamazepine, clonazepam, and lamotrigine) was transported
by BCRP. However, Nakanishi et al. (123) reported that the
brain-to-plasma concentration ratio values of phenobarbital,
clobazam, zonisamide, gabapentin, tiagabine, and levetiracetam
were higher in mdr1a/b/Bcrp triple knockout mice than those in
mdr1a/b double knockout mice, suggesting the involvement of
BCRP in the transport of these ASDs. Subsequently, Römermann
et al. (121) reported BCRP transport of lamotrigine using CETA
in MDCKII cells transfected with murine Bcrp or human BCRP,
but did not observe transport of phenytoin, phenobarbital, carbamazepine, levetiracetam, topiramate, or valproate. Together,
current evidence suggests that most ASDs are not transported
by BCRP, though discrepancies exist between in vitro and in vivo
findings (121).
In summary, available data support the transporter substrate
status of some ASDs, but overall the evidence is inconsistent and
incomprehensive. There is a continued need to systematically
investigate the transporter substrate status of ASDs using in vivo
and in vitro models and eventually to confirm the findings in
epilepsy patients (96).

Mechanisms of Efflux Transporter Upregulation in Epilepsy

An important question that stems from the transporter hypo
thesis is whether overexpression of efflux transporters at the
blood–brain barrier observed in epilepsy is acquired or constitutive. Current evidence suggests that seizures, genetic factors, or
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P-gp expression levels (130, 131). If P-gp levels were already
maximally induced in the study of Wang-Tilz et al. (129), one
would not expect to see additional increases in P-gp expression
levels by ASDs. Consistent with this, Wen et al. (132) reported that
21-day exposure of naïve rats to phenobarbital, carbamazepine,
or phenytoin given orally twice daily significantly increased P-gp
activity and protein expression levels in capillary endothelial cells
in cerebral cortex and hippocampus. The underlying mechanism
of this induction was not investigated, but the authors speculated that the observed effect was due to ASD activation of the
ligand-activated transcription factors pregnane X receptor and/
or constitutive androstane receptor (132). In contrast, Ambroziak
et al. (133) did not observe any changes on P-gp expression or
activity levels in the GPNT rat brain endothelial cell line and the
MDCKII cell line that were exposed to phenobarbital, phenytoin,
or carbamazepine. In this regard, it is important to note that
ASD-mediated upregulation of drug efflux transporters at the
blood–brain barrier and in other tissues does not explain why
some patients are resistant to the very first ASD they are given.
While this speaks against the theory that ASDs are the main cause
for drug resistance due to transporter upregulation, it is possible
that ASDs are one contributor, among others, to refractory epilepsy. Clearly, further studies are needed to draw firm conclusions
on the effect of ASDs on P-gp expression and activity levels in the
brain and their contribution to overall drug resistance in epilepsy.
The second mechanism that has been shown to result in
increased efflux transporter expression levels is through recurring seizures. In this regard, Lazarowski et al. (134) showed that
daily administration of 3-mercaptopropionic acid (MP) causes
daily seizures, which result in a progressive increase of P-gp
protein expression at the blood–brain barrier. Furthermore, these
researchers showed that the pharmacokinetics of phenytoin are
altered in the hippocampus of MP-induced epileptic rats and
that treatment with the P-gp inhibitor nimodipine restored
normal hippocampal pharmacokinetics of phenytoin resulting
in seizure control (135). More recently, the MP-induced seizure
model in mice has been presented as a new drug-resistant model
that allows screening of drugs at early stages of preclinical trials. After 23 consecutive MP administrations, 100% of animals
became resistant to phenytoin and 80% of animals developed
resistance to phenobarbital. Resistance was strongly associated
with overexpression of P-gp in the cerebral cortex, hippocampus,
and striatum. Importantly, resistance to drugs that are not P-gp
substrates such as carbamazepine, diazepam, or levetiracetam
was not observed (136). Therefore, this new model could be useful for screening novel ASDs that are P-gp substrates and have
the potential to control seizures in pharmacoresistant epilepsy.
The molecular signaling mechanism underlying increased
efflux transporter expression levels in epilepsy has been studied
by our group and others. In this regard, we recently showed that
seizure-induced glutamate release triggers a signaling pathway
that involves the N-methyl-d-aspartate receptor, cyclooxygenase-2, and the prostanoid E1 receptor, resulting in increased
P-gp protein and activity levels at the blood–brain barrier
(131, 137–139). In addition, evidence from in vitro and in vivo
rodent studies suggests that targeting this pathway could control P-gp expression and activity levels, and thus, help increase
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ASD brain penetration and improve ASD efficacy to control
seizures in drug-resistant epilepsy (131, 137–139). One study
of Salvamoser et al. (140) showed that exposing isolated porcine
brain capillaries and human brain capillaries from ASD-resistant
patients with FCD to glutamate resulted in reduced BCRP protein expression levels. This finding is in contrast with data from
human studies comparing BCRP expression between control
and epileptic human brain tissue (89, 90, 92, 95), and unpublished data from our lab clearly demonstrate seizure-induced
upregulation of BCRP protein expression and activity levels in
brain capillaries from chronic epileptic rats. Considering that
Salvamoser et al. neither provided data from dose response
nor conducted time course experiments, the observed effect
on BCRP in porcine brain capillaries could also be due to
glutamate-mediated excitotoxicity. This could also explain the
authors’ observation in brain capillaries from epileptic human
brain tissue. In this case, capillaries were isolated from resected
epileptic brain tissue that has already been exposed to glutamate
released during seizures, and thus, adding additional glutamate
ex vivo will most likely have caused excitotoxicity. Thus, the
authors could have misinterpreted glutamate-mediated excitotoxicity as BCRP downregulation.
Together, in vivo and in vitro experimental data support P-gp
upregulation in the epileptic brain as a result of glutamate release
and the downstream signaling pathway. Nevertheless, signaling
mechanisms that control P-gp and other efflux transporters at
the blood–brain barrier have to be first confirmed at the human
blood–brain barrier prior to translational development of this
strategy (124).

Polymorphisms of Efflux Transporters and ASD Response

Hoffmeyer et al. (141) were the first to identify a synonymous
C3435T SNP in exon 26 of the human ABCB1 (MDR1) gene. In
this particular study, individuals with the TT genotype had statistically significantly lower intestinal P-gp protein expression and
activity levels as demonstrated by enhanced intestinal uptake of
the P-gp substrate digoxin (141). Several other ABCB1 polymorphisms have been identified later, including a non-synonymous
G2677T/A SNP in exon 21 and a synonymous C1236T SNP on
exon 12, both of which are thought to be in linkage disequilibrium with C3435T (142) and account for the majority of the
ABCB1 haplotypes along with the C3435T SNP (78). Since the
first description of the association between the C3435T SNP
and P-gp expression and activity levels, numerous studies have
been conducted in an attempt to replicate the results or identify
other relevant polymorphisms (143). However, follow-up studies provided conflicting results. For example, Siegmund et al.
(144) reported that in healthy Caucasian individuals, none of
the genotypes studied, including C3435T, G2677T/A, and other
putatively functional SNPs, significantly affected duodenal P-gp
protein expression levels or P-gp in vivo activity.
Similarly, researchers investigating the association between
ABCB1 polymorphisms and response to ASD treatment found
inconsistent results. Siddiqui et al. (11) were the first to investigate ASD resistance in relationship to ABCB1 polymorphisms.
In a study with 315 epilepsy patients, the authors reported that
patients with refractory epilepsy had a higher frequency of the
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CC genotype at the C3435T SNP than the TT genotype. However,
Tan et al. (145) could not confirm the association between the
C3435T SNP and ASD response in epilepsy. Sills et al. (146)
studied the association between the C3435T SNP and pharmacoresistance in 400 epilepsy patients and found no significant differences in allele or genotype frequency between ASD responders
and non-responders. Tate et al. (60) reported a lack of association
between the C3435T SNP with phenytoin or carbamazepine
dosing. Similarly, a study investigating the association between
the C3435T polymorphism and drug resistance in 171 Korean
patients with epilepsy yielded a negative result (147). Shahwan
et al. (148) studied 440 Irish patients with epilepsy and they also
could not detect significant associations between ASD resistance
and C3435T or seven other functional variants in the ABCB1
gene.
Using a gene-wide approach, Kwan et al. (142) genotyped 12
tagging and candidate SNPs of ABCB1 in 464 Chinese patients
with epilepsy and revealed significant associations between
drug resistance and the intronic polymorphism rs3789243, the
coding polymorphism G2677T/A, and haplotypes containing
two polymorphisms. In contrast, Leschziner et al. (149) found
no significant association between multidrug resistance and
C3435T, G2677T/A, C1236T, or a set of tagging SNPs that des
cribe common variations in ABCB1 in a case–control study with
149 Caucasian epilepsy patients.
Such discrepancies in study results could imply that there is
no true association between the ABCB1 C3435T polymorphism
with ASD resistance in epilepsy. An alternative explanation
could be that the association was masked by confounding
factors such as heterogeneity in the types of ASDs used in the
studies, because not all ASDs are P-gp substrates or transported
to the same extent (8, 148). Differences in seizure types and
definitions of ASD resistance also add to the overall complexity
(143, 148). Nevertheless, results from some recent meta-analyses
demonstrate that negative findings persist even after controlling
for some of the confounding factors. In this regard, Bournissen
et al. (150) conducted a meta-analysis of 11 case–control studies
(total of 3,371 patients) and investigated the relationship between
ABCB1 C3435T polymorphisms and ASD response. The authors
did not find a significant association between the ABCB1 C3435T
SNP and ASD response (odds ratio 1.15; 95% confidence interval
0.78–1.70; p = 0.48). Stratification of studies by the ethnicity of
the subjects yielded similar results. A meta-analysis conducted
by Haerian et al. (151) included 22 genetic association studies
(total of 6,755 patients) and also did not identify a significant
association between ABCB1 C3435T polymorphisms and ASD
response (odds ratio 1.06, 95% confidence interval 0.98–1.14,
p = 0.12). Stratified subgroup meta-analyses based on the new
definition of drug-resistant epilepsy proposed by the ILAE and
based on ethnicity did not reveal any significant associations
either (151). Thus, Haerian et al. (152) conducted another metaanalysis to evaluate the association between the ABCB1 C1236T,
G2677T/A, and C3435T loci and ASD response. A total of 26
publications (n = 7,831 patients in total) were included for a
haplotype meta-analysis, which did not reveal any significant
correlation of the polymorphisms and their haplotypes with
ASD response either in the general population or in individual
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ethnic groups. Nevertheless, the authors pointed out that the
available data did not allow subgroup analyses based on other
confounders, such as types of ASDs used or types of epilepsy
(152). Thus, an association between ABCB1 polymorphisms and
P-gp expression and activity levels in patients with refractory
epilepsy needs to be confirmed in brain tissue first before the role
of ABCB1 polymorphisms in ASD resistance can be accepted
(153). If there was conclusive evidence for C3435T genotypedependent P-gp expression at the blood–brain barrier, a lack of
association between ABCB1 polymorphisms and ASD response
could potentially negate the role P-gp plays in refractory epilepsy
(146). Nevertheless, at present there is inadequate evidence
supporting the relationship between ABCB1 polymorphisms
and brain ABCB1 mRNA or P-gp protein expression levels in
refractory epilepsy (92, 142, 153).
Even less studied is the role of how ABCC2 polymorphisms
could affect pharmacoresistance in epilepsy, and studies published so far have yielded inconsistent results. In two recently
published meta-analysis studies, the researchers investigated the
relationship between three common ABCC2 SNPs (c.-24C>T,
c.1249G>A, and c.3972C>T) and ASD response and found a
significant association between ASD resistance and c.-24C>T,
but not with the other two SNPs (154, 155). However, authors of
both reports noted some limitations to their findings, including
ethnicity differences in the identified association and variability
in how ASD resistance was defined among the studies (154, 155).
In contrast, two other meta-analyses identified a significant
association between ABCC2 c.1249G>A and pharmacoresistance
(156, 157). The discrepancy in results could be explained by the
heterogeneity in the enrolled studies, and thus, current findings
need to be confirmed with larger well-designed studies (155).

Overcoming Pharmacoresistance with Transporter Inhibitors

One potential strategy to overcome ASD resistance is by directly
inhibiting the efflux transporters assumed to be in part responsible for this phenomenon. For P-gp, there are four generations
of inhibitors (158). First-generation inhibitors are non-specific
for P-gp, such as cyclosporine A and verapamil (2). Secondgeneration inhibitors [e.g., PSC833 (valspodar), a cyclosporine
A analog] are more specific for P-gp, but they still interfere with
cytochrome CYP3A4 metabolizing enzyme (2). Third-generation
P-gp inhibitors are P-gp-specific and do not interfere with drug
metabolizing enzymes (2, 158). Tariquidar (XR9576) in particular
is a non-competitive P-gp inhibitor with greater affinity for P-gp
than its substrates (20). Finally, fourth-generation P-gp inhibitors (e.g., the cyclic peptide QZ59SE and the natural compounds
lamellarin and gomisin A) display low toxicity but high selectivity
and potency are currently under development and evaluated for
their use in humans (158, 159). MRP inhibitors include probenecid, MK-571, and LY402913 (2). Probenecid effectively inhibits
MRPs, especially MRP1 and MRP2 (116).
Experimental data support the concomitant use of P-gp/MRP
inhibitors with ASDs as a strategy to increase anticonvulsant brain
uptake and efficacy and overcome pharmacoresistance in animal
models. Clinckers et al. (104) demonstrated in an in vivo microdialysis study that inhibition of P-gp/MRPs using verapamil/
probenecid counteracted pharmacoresistance to oxcarbazepine

12

July 2017 | Volume 8 | Article 301

Tang et al.

Drug Resistance in Epilepsy

in rats that had experienced pilocarpine-induced seizures. Brandt
et al. (47) conducted a study with TLE rats that were divided into
two groups based on their response/non-response to phenobarbital at the maximum tolerated doses and found that tariquidar
completely counteracted pharmacoresistance. In a similar study,
van Vliet et al. (48) first demonstrated that therapeutic doses of
phenytoin only partially controlled seizures in chronic epileptic
rats where P-gp levels were upregulated in the ventral hippocampus and entorhinal cortex, which was determined by Western
blotting of the homogenized brain areas. When coadministered
with tariquidar, phenytoin brain concentrations significantly
increased and seizures were almost completely controlled (48).
Verapamil, nifedipine, and diltiazem have also been coadministered with ASDs to inhibit P-gp and been evaluated for their
effect in increasing ASD brain levels and consequently reducing
seizures in patients in clinical practice. Because calcium channel
blockers can have intrinsic anticonvulsant activity and inhibitory effect on CYP3A4, it could be difficult to differentiate the
effect on P-gp inhibition (2, 160). Several case reports show that
adding verapamil to an ASD regimen improved seizure control
(160–162). One pilot non-placebo-controlled open-label study
in 19 adult patients with refractory TLE found that adding
verapamil (120 mg daily in 13 patients and 240 mg daily in 6
patients) to the existing ASD treatment improved seizure control
in a dose-dependent manner; in seven patients seizure frequency
was reduced by at least 50% (163). In the first randomized,
double-blinded placebo-controlled trial that was conducted to
evaluate the safety and efficacy of once daily 240 mg verapamil as
an add-on therapy in refractory epilepsy patients with focal onset
seizures, no statistically significant decrease in seizure frequency
was observed in the 12 patients who finished the study; none of
the patients achieved 50% or more seizure reduction (164). In this
study, adverse effects unique to the verapamil group included skin
rashes and feet edema, while no cardiovascular adverse effects
were reported. A more recent non-placebo-controlled open-label
study explored the efficacy of low-dose verapamil (20 mg three
times daily) as adjunctive treatment in refractory epilepsy (165).
The authors reported that 10 out of 19 patients who remained
in the study achieved 50% or more seizure reduction, and none
of the patients experienced cardiovascular or hemodynamic
adverse events (165).
Together, the major limitations of these clinical studies are
their small patient group size and the use of relatively unspecific
P-gp inhibitors (e.g., verapamil), and thus, no firm conclusion
about the efficacy of add-on P-gp inhibitors in refractory epilepsy
can be drawn at present. This is especially true given the discrepancy in findings from open-label and double-blinded studies.

ASD-responsive rats, and P-gp inhibition with a specific inhibitor, such as tariquidar, counteracts ASD resistance (59, 166).
However, whether such findings from rodent studies can be
extrapolated to refractory epilepsy in human patients is unclear
(59, 166). It is also unclear if seizure-induced P-gp upregulation
at the blood–brain barrier has clinically relevant effects on ASD
brain delivery and ultimately on ASD efficacy in epilepsy patients,
or if P-gp upregulation is no more than an epiphenomenon of
uncontrolled seizures (45).
In vitro evidence shows that most ASDs are weak substrates of
human P-gp at best (167), but it has also been argued that significant overexpression of multidrug transporters may still restrict
ASD access to epileptic neurons in vivo (45). On the other hand,
as revealed by several meta-analyses, the transporter hypothesis
is not supported by genetic association studies (167). Clinical
evidence supporting efflux transporter-mediated ASD transport
in the human brain has not been demonstrated yet (166). Recent
studies utilizing PET/MR imaging, however, demonstrate for
the first time increased P-gp transport activity in patients with
drug-resistant epilepsy and that seizure reduction after surgery
leads to a decrease in P-gp overactivity (100, 168). Together,
these patient data suggest that an optimal outcome after surgery
is associated with a reduction in P-gp transport activity and that
P-gp overexpression could serve as a surrogate marker for drugresistant epilepsy.
In order to fully assess if P-gp upregulation has any relevant
consequences on pharmacoresistance, studying P-gp expression
in brain tissue from both ASD-responsive and ASD-resistant
patients and/or conducting PET imaging using P-gp substrates
or inhibitors in patients would be critical (45, 166). At present,
aspects of the transporter hypothesis are still controversial, and
further research is needed to determine the clinical relevance of
efflux transporter overexpression at the blood–brain barrier.

CONCLUSION
Despite the introduction of newer generations of ASDs, pharmacoresistance remains one of the biggest challenges in epilepsy
treatment. In this review article, we summarize various theories
that have been proposed to explain the mechanism(s) underlying refractory epilepsy with an emphasis on the transporter
hypothesis.
The pharmacokinetic hypothesis is supported by case reports
that describe subtherapeutic ASD plasma levels in refractory
patients, but additional substantiating evidence from animal or
human studies is lacking. The neural network hypothesis was
inspired by molecular evidence showing the existence of signaling
molecules that guide the abnormal growth of axons in epilepsy,
but this hypothesis is limited by its inability to account for the
occurrence of pharmacoresistance in some but not all epilepsy
patients. The intrinsic severity hypothesis is supported by the
clinical finding that high frequency of pretreatment seizures is
associated with refractoriness, but it fails to explain the complex
temporal patterns of ASD resistance in some patients, and a
mechanistic explanation behind this hypothesis is also lacking.
The gene variant hypothesis is supported by some identified associations between gene variations and ASD resistance, but study

Summary

Sisodiya (6) proposed that a mechanism causing refractory
epilepsy needs to be involved in ASD resistance with appropriate
functionality and presence in the epileptogenic brain region, and
counteracting such a mechanism should reduce refractoriness.
In the rodent model, overexpression of P-gp has been observed
in epileptic brain tissue, and such overexpression correlates
with reduced brain ASD concentrations. Indeed, ASD-resistant
rats have higher brain P-gp protein expression levels than
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findings are often inconsistent and need to be confirmed in larger
populations. The strongest evidence for the target hypothesis
exists for the loss of use-dependent sodium channel blockade by
carbamazepine, but beyond this observation its general utility is
limited. Finally, as the most cited hypothesis of refractory epilepsy,
the transporter hypothesis is strongly supported by evidence of
efflux transporter overexpression at the blood–brain-barrier, but
other aspects of the hypothesis remain controversial, especially
the clinical relevance of efflux transporter overexpression and the
transporter substrate status of many ASDs.
It is clear from current evidence that pharmacoresistance in
epilepsy is a multifactorial phenomenon, but based on existing
evidence more work is needed to reinforce and integrate the current theories with the ultimate goal of guiding the development
of better epilepsy therapies.

mechanism plays a major role in resistance to carbamazepine, as
there is conflicting evidence on its P-gp substrate status.
Although the majority of the literature focuses on the transporter hypothesis, further evidence on the clinical relevance of
efflux transporter overexpression in refractory epilepsy is still
needed. PET studies using P-gp ligands can be used to investigate how P-gp expression and activity is changed in epilepsy and
potentially be used to identify patients who can benefit from the
use of P-gp inhibitors in the future (17). Until more data become
available, it is fair to say that transporter overexpression is most
likely not the only factor that plays in ASD resistance and that
the best evidence available only supports the plausibility for the
clinical role of efflux transporters in refractory epilepsy.

Treatment Strategies

Based on the transporter hypothesis, one strategy to counteract
pharmacoresistance in epilepsy is the adjunctive use of P-gp
inhibitors (59). However, the use of P-gp-specific inhibitors is not
without concerns as systemic inhibition of P-gp could increase
plasma concentrations of drugs and toxins, potentially leading to
systemic toxicity (20, 44). The use of a non-specific P-gp inhibitor,
such as verapamil, can be limited by its effect on heart rate and
blood pressure (160). Though one small open-label study showed
that low-dose verapamil was well tolerated (165), this finding still
needs to be confirmed in larger double-blinded studies. Another
approach we and others suggested is modulating transporter regulation in epilepsy without affecting basal transporter expression
and function (131, 137–139). Other strategies include developing
new ASDs that are not substrates of efflux transporters (102) and
bypassing these transporters using targeted delivery systems (12).
Intranasal administration of ASDs has been proposed, but more
pharmacokinetic evidence on whether intranasal administration
enhances brain delivery of drugs is needed. Intracerebral administration is another option, but the invasive nature of the method
limits its application (124).
One important approach to improve the prognosis of epilepsy is to develop new ASDs with greater efficacy, such as by
targeting mechanisms unaffected by current ASDs (14, 171).
Consequently, there is a need to enhance the understanding of
the neurobiological mechanisms underlying ASD resistance in
patients and to identify and test novel treatments using various
models, including animal models of refractory epilepsy (14, 17).
In addition, efforts should be made to search for drugs able to
interfere with the progression of epilepsy or hinder neurodegeneration (17).
Several non-pharmacological strategies are currently under
development. Stem cell-based therapies and gene therapy are
promising strategies, but they have not been tested in clinical trials for epilepsy (172, 173). Potential mechanisms of gene therapy
include inhibiting neuronal hyperexcitability, promoting neuronal survival, and facilitating circuit repair by transduction of
endogenous cells and expression of modulators or neurotrophic
factors. Stem cell-based therapies can be used to replace damaged
or dead neurons, provide trophic support to facilitate neuronal
survival and repair, or act as a platform for ex vivo gene therapy
where transplanted neurons are genetically modified to produce
therapeutic substances (172).

FUTURE PERSPECTIVES
Current Status and Future Development
of Treatment Guidelines

The American Academy of Neurology and the American Epilepsy
Society guidelines on the treatment of refractory epilepsy were
last updated in 2004. These guidelines conclude that all newer
ASDs evaluated (gabapentin, lamotrigine, topiramate, tiagabine,
oxcarbazepine, levetiracetam, and zonisamide) are appropriate
for adjunctive therapy in refractory partial epilepsy in adults (7).
However, such recommendations were made in the absence of
head-to-head clinical trials that were rationally designed to evaluate the efficacy of two or more ASDs at comparable doses (7). Two
other sets of guidelines by the American Academy of Neurology
published in 2003 and 2013, respectively, conclude that anteromesial temporal lobe resection in patients with disabling complex
partial seizures is more beneficial than continuing pharmacotherapy, and that vagus nerve stimulation is possibly useful for
treating children with epilepsy and patients with Lennox–Gastaut
syndrome (169, 170). These treatment guidelines recognize the
limitations of current treatment options and the scarcity of
quality evidence for treating refractory epilepsy. Nevertheless, in
addition to incorporating recent clinical evidence, future treatment guidelines need to place more emphasis on personalizing
the therapy of patients with refractory epilepsy. In this regard,
factors specific to individual patients such as disease etiology,
medical history, drug response, temporal patterns of refractoriness, as well as the multifactorial nature of pharmacoresistance
need to be taken into account to improve therapy of patients with
refractory epilepsy.

Further Development of Current
Hypotheses

Each of the current hypotheses has its limitations, and although
each individual theory is applicable to a subgroup of patients,
some of these mechanisms may overlap in patients (59). Spe
cifically, it has been proposed that the target hypothesis and the
transporter hypothesis are not mutually exclusive and that one
mechanism could be predominant for some ASDs but not for
others. For example, Remy and Beck (63) proposed that the target
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